Michael Maschio

588 total citations
30 papers, 400 citations indexed

About

Michael Maschio is a scholar working on Epidemiology, Health and Oncology. According to data from OpenAlex, Michael Maschio has authored 30 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 10 papers in Health and 9 papers in Oncology. Recurrent topics in Michael Maschio's work include Vaccine Coverage and Hesitancy (10 papers), SARS-CoV-2 and COVID-19 Research (7 papers) and Influenza Virus Research Studies (7 papers). Michael Maschio is often cited by papers focused on Vaccine Coverage and Hesitancy (10 papers), SARS-CoV-2 and COVID-19 Research (7 papers) and Influenza Virus Research Studies (7 papers). Michael Maschio collaborates with scholars based in United States, United Kingdom and Canada. Michael Maschio's co-authors include Milton C. Weinstein, Michele Kohli, Michael Drummond, Ayman Chit, Carlos A. DiazGranados, J Mould-Quevedo, Nicole Ferko, Frieder Braunschweig, Cecilia Linde and Yves Verboven and has published in prestigious journals such as Journal of Clinical Epidemiology, Annals of Oncology and The Lancet Infectious Diseases.

In The Last Decade

Michael Maschio

28 papers receiving 394 citations

Peers

Michael Maschio
Ida Rask Moustsen‐Helms Denmark
Marina Bakker Netherlands
Sarah Geoghegan Ireland
Jason K. H. Lee Canada
Ali Nizar Latif Qatar
Héctor Alexander Velásquez García Canada
Nikolaos Spanakis Greece
Marielle Fricchione United States
Zhuoru Zou China
Farheen Malik Pakistan
Ida Rask Moustsen‐Helms Denmark
Michael Maschio
Citations per year, relative to Michael Maschio Michael Maschio (= 1×) peers Ida Rask Moustsen‐Helms

Countries citing papers authored by Michael Maschio

Since Specialization
Citations

This map shows the geographic impact of Michael Maschio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Maschio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Maschio more than expected).

Fields of papers citing papers by Michael Maschio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Maschio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Maschio. The network helps show where Michael Maschio may publish in the future.

Co-authorship network of co-authors of Michael Maschio

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Maschio. A scholar is included among the top collaborators of Michael Maschio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Maschio. Michael Maschio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kohli, Michele, Michael Maschio, Keya Joshi, et al.. (2024). The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom. Journal of Medical Economics. 27(1). 1359–1372. 2 indexed citations
2.
Joshi, Keya, Ekkehard Beck, Michael Maschio, et al.. (2024). The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines. 12(4). 434–434. 1 indexed citations
3.
Joshi, Keya, Stefan Scholz, Michael Maschio, et al.. (2023). Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany. Journal of Medical Economics. 27(1). 39–50. 9 indexed citations
4.
Kohli, Michele, Michael Maschio, Keya Joshi, et al.. (2023). The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States. Journal of Medical Economics. 26(1). 1532–1545. 16 indexed citations
5.
6.
Maschio, Michael, Michele Kohli, Simron Singh, et al.. (2020). A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics. 38(6). 607–618. 3 indexed citations
7.
8.
Maschio, Michael, Simron Singh, D. Mark Pritchard, et al.. (2017). A Budget Impact Model of The Addition of Telotristat Ethyl Treatment In Patients With Uncontrolled Carcinoid Syndrome. Value in Health. 20(9). A548–A549. 2 indexed citations
9.
Li, Xiaoyan, Michael Maschio, Guillermo Villa, et al.. (2016). Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma. PharmacoEconomics. 35(4). 425–438. 24 indexed citations
10.
Maschio, Michael. (2016). The Actor Prepares.
11.
12.
13.
Kohli, Michele, Raymond Farkouh, Michael Maschio, et al.. (2015). Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion. Health Affairs. 34(7). 1234–1240. 6 indexed citations
14.
Li, Xiaoyan, Michael Maschio, Richard Barron, et al.. (2014). Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. Gynecologic Oncology. 133(3). 446–453. 8 indexed citations
15.
Maschio, Michael, Rich Barron, Milton C. Weinstein, et al.. (2013). Cost-Effectiveness Of Prophylaxis Treatment Strategies For Febrile Neutropenia In Recurrent Ovarian Cancer Patients. Value in Health. 16(3). A140–A140.
16.
17.
18.
Reboli, Annette C., Coleman Rotstein, Daniel H. Kett, et al.. (2011). Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis. PharmacoEconomics. 29(8). 705–717. 20 indexed citations
19.
20.
Bellamy, Nicholas, Mary Bell, Charlie H. Goldsmith, et al.. (2009). BLISS index using WOMAC index detects between-group differences at low-intensity symptom states in osteoarthritis. Journal of Clinical Epidemiology. 63(5). 566–574. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ida Rask Moustsen‐Helms Breakdown of academic impact, for papers by Marina Bakker Breakdown of academic impact, for papers by Sarah Geoghegan Breakdown of academic impact, for papers by Jason K. H. Lee Breakdown of academic impact, for papers by Ali Nizar Latif Breakdown of academic impact, for papers by Héctor Alexander Velásquez García Breakdown of academic impact, for papers by Nikolaos Spanakis Breakdown of academic impact, for papers by Marielle Fricchione Breakdown of academic impact, for papers by Zhuoru Zou Breakdown of academic impact, for papers by Farheen Malik
Rankless by CCL
2026